ArticleAntiviral research2017
Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.
Tsuyoshi Hayashi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this papercites it